APO

Editor's Note: There is a photo and a video associated with this release.

On October 24, 2011 The Howard Group hosted its 3rd annual "Opportunity Knocks" investor conference in Calgary. Tina Sampalis, President of Acasti (TSX VENTURE:APO) provided an overview of the company to an audience of investment advisors & private investors.

A recording of the presentation is now available online. Click here to view - http://www.howardgroupinc.com/Portals/0/Acasti/presentation_vid/index.html

Highlights on Acasti are as follows:

--  Founded 2008 - Listed 03/2011 (TSX VENTURE:APO) 
    Subsidiary of Neptune Technologies 
--  NKO Krill based Omega-3 Phospholipid products focused on natural
    cholesterol management. Decreases Triglycerides; Decreases LDL (bad
    cholesterol); Increases HDL (good cholesterol); Potential enhancer of
    Statin therapy; Potential use in Statin intolerant patients. 
--  Full access to Neptune's manufacturing & intellectual property. 
--  Very recently, Neptune & Acasti were granted an important patent, which
    is key for both companies in relation to the U.S. market. 
--  LAST WEEK Doug Loe at Byron Capital Markets gave this company a BUY
    rating with a $3.50 target price. 

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

To view the fact sheet associated with this release, please see the following link: http://media3.marketwire.com/docs/Acasti_Factsheet.pdf

To view the photo associated with this release, please see the following link: http://www.marketwire.com/library/20111110-Acasti800.jpg

Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Acasti Pharma Inc. Tina Sampalis President +1 450.686.4555t.sampalis@acastipharma.com Acasti Pharma Inc. Xavier Harland Chief Financial Officer +1.450.687.2262x.harland@acastipharma.comwww.acastipharma.com The Howard Group Dave Burwell (888) 221-0915dave@howardgroupinc.comwww.howardgroupinc.com

Acasti Pharma Inc. (TSXV:APO)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Acasti Pharma Inc. (TSXV:APO)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024